HOME >> MEDICINE >> NEWS
The Burroughs Wellcome Fund awards $8 million to infectious disease investigators

RESEARCH TRIANGLE PARK, N.C. -- When the 16 recipients of the Burroughs Wellcome Fund's Investigators in Pathogenesis of Infectious Disease award were notified that they had received the award, there was more good news. The award amount had increased to $500,000 over a five-year period from $400,000.

The Investigators in Pathogenesis of Infectious Disease awards are made to encourage aggressive, multidisciplinary approaches to investigating pathogenesis. BWF launched the program in 2002 and has made 58 awards for an investment of approximately $24.8 million in the careers of investigators who are working on understanding the interaction between the human host and the infectious agentbacterial, viral, fungal, or parasitic.

All awardees hold tenure-track faculty positions and must be nominated by degree-granting institutions in the United States or Canada.

"The constant threat of infectious disease is of global concern, BWF President Dr. Enriqueta Bond said. "Understanding the underlying principles of how the microbial world interacts with the human host is of paramount importance. We are pleased to play a role in the expansion of knowledge in this important scientific field.

Following are the 2007 award recipients, along with their institutions and research projects:

Benjamin K. Chen, M.D., Ph.D.
Mount Sinai School of Medicine
Dissemination of HIV through virological synapses

Andrew Darwin, Ph.D.
New York University School of Medicine
Mechanisms of Pseudomonas aeruginosa tolerance to secretin-induced stress during host infection

Michael R. Farzan, Ph.D.
Harvard Medical School
Parallel identification of obligate viral receptors

Britt Glaunsinger, Ph.D.
University of California-Berkeley
Global modulation of cellular gene expression by an oncogenic human herpesvirus

Karen J. Guillemin, Ph.D.
University of Oregon
Reg
'"/>

Contact: Russ Campbell
news@bwfund.org
919-991-5119
Burroughs Wellcome Fund
4-Jun-2007


Page: 1 2

Related medicine news :

1. Wellcome brain insights
2. University hospitals wins multiple national IT awards for electronic patient data bank
3. CIRM awards $3.79 million to Burnham Institute
4. Gerontological Society of America awards new Hartford Doctoral Fellowships
5. AACR awards minority and other underrepresented scientists
6. FNSNA awards $25,000 grant to Rutgers College of Nursing
7. International and American Associations for Dental Research present awards and fellowships
8. JDRF awards Emory $2.5 million to develop islet transplant technology
9. NIH awards $1 million to Temple University Hospital for neurological treatment studies
10. NHLBI awards 12 Womens Health Initiative contracts
11. The Gerontological Society of America awards new Hartford Doctoral Fellowships

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: